FLORATOPIC

Atopic dermatitis (AD) is a prevalent inflammatory skin condition characterized by recurrent episodes, dry skin, erythema, and itching [1]. The incidence of AD has been increasing, particularly with the rise of industrialization and urbanization, and it now affects 15-30% of children and 10% of adults globally [2]. AD's pathophysiology is multifaceted, involving an altered immune response towards Th2 immunity and defects in the innate immune system. Predisposing factors for AD include smaller family size, urban living, and a Western diet, all of which impact both skin and gut microbiota [2]. AD typically begins in early childhood and often marks the onset of the "atopic march," which may progress to asthma, allergic rhinitis, and allergic conjunctivitis.

FLORATOPIC® has been specifically formulated and clinically tested to address AD in infants, adults, and children, utilizing the immunomodulatory properties of Ligilactobacillus salivarius LS01 [3-6]. The clinical and immunological efficacy of LS01 in AD is attributed to its regulation of the Th1/Th2 cytokine ratio, rather than a mere increase in the expression of Th1 cytokines. LS01 is known to enhance the production of IL-12, critical for Th1 development.

In two clinical studies involving both adults and children with AD (including moderate/severe cases in adults), 16 weeks of FLORATOPIC® supplementation led to significant improvements in the Dermatology Life Quality Index (DLQI), SCORAD score, and itching index [4,5]. These improvements persisted for 4 weeks after the end of probiotic supplementation. Furthermore, in a double-blind, placebo-controlled randomized controlled trial (RCT) in adults, FLORATOPIC® supplementation:

• Rebalanced the intestinal microflora: significantly decreased fecal staphylococci load and LPS plasma concentration (with effects persisting post-treatment), while increasing fecal LS01 content (LS01 was recovered in all subjects after treatment).

• Improved Th1 cytokine stability, even during pollen season.